Introduction
============

Autoinflammatory diseases arise from disorders of the innate immune system \[[@B1]\]. The prototype disease is familial Mediterranean fever (FMF), which belongs to the group of hereditary recurrent fevers. Periods of inflammation are predominantly triggered following unnoticed proinflammatory signals. The levels of serum markers of inflammation such as C-reactive protein are always increased during attacks, however autoantibodies remain mostly undetectable. Since the discovery in 1997 of the gene responsible for FMF \[[@B2],[@B3]\], dramatic insights have been gained through establishing the central role of the inflammasomes by unraveling their components and interacting cellular partners \[[@B4]-[@B6]\]. Subsequent to the identification of causal mutations in monogenic autoinflammatory diseases, several sequence variants in the causative genes were found to act as susceptibility factors in the more common multifactorial diseases such as rheumatoid arthritis or multiple sclerosis \[[@B7]\]. More recently, monogenic autoinflammatory disorders expanded to include the so far-called inflammatory skin diseases without systemic involvement. Enhanced knowledge relating to the critical physiological mechanisms altered in these diseases fuelled the development of novel, dramatically effective targeted biological drugs such as Interleukin-1 inhibitors \[[@B8]\]. As autoinflammatory diseases are rare, a national referral center nominated by the French ministry of health was set-up (CeRéMAI; \[<http://asso.orpha.net/CEREMAI/EN/index.html>\]) in order to improve care for patients. This referral center created Infevers \[[@B9]\] \[fmf.igh.cnrs.fr/infevers/\], a dedicated online database for autoinflammatory mutations \[[@B9]\].

This review focuses on monogenic autoinflammatory diseases identified within the last five years, including epidemiological and genetic data (Table  [1](#T1){ref-type="table"}), an exhaustive description of the corresponding disease name and synonyms where available, OMIM and Orphacode numbers, main clinical signs and therapeutic approaches (Table  [2](#T2){ref-type="table"}).

###### 

Epidemiology and genetics of rare recently recognized monogenic autoinflammatory diseases

  **Year of gene discovery**   **Disease\***                                                                                               **N patients\*\***       **M/F ratio**   **Ethnicity\*\*\***          **Ref**   **Mode of inheritance**   **Gene\*\*\*\***                                                        **Chromosome location**   **Most frequent mutation**
  ---------------------------- ------------------------- --------------------------------------------------------------------------------- ------------------------ --------------- ---------------------------- --------- ------------------------- ------------------ ---------------------------------------------------- ------------------------- ---------------------------------
  2008                         H Syndrome                Histiocytosis lymphadenopathy plus syndrome                                       4                        2/2             1 Indian case                12        Recessive                 *SLC29A3*          Solute Carrier Family                                10q22.1                   ND
  1 Pakistani case             13                                                                                                                                                                                                                                                                                                                      
  1 Morocan case               10                        29 (Nucleoside Transporter), Member 3                                                                                                                                                                                                                                                         
  1 Tunisian case              11                                                                                                                                                                                                                                                                                                                      
  2008                         NAPS12                    NLRP12 Associated Periodic Syndrome                                               19                       13/6            2 Guadeloupean families      18        Dominant                  *NLRP12*           NLR pyrin domain containing protein 12               19q43.42                  c.1054C\>T, p.Arg352Cys
  17                                                                                                                                                                                                                                                                                                                                                   
  1 Italian family             58                                                                                                                                                                                                                                                                                                                      
  6 Eastern-European cases     16                                                                                                                                                                                                                                                                                                                      
  1 Armenian case              16                                                                                                                                                                                                                                                                                                                      
  1 Italian case               9                                                                                                                                                                                                                                                                                                                       
  1 Guadeloupean case          9                                                                                                                                                                                                                                                                                                                       
  1 Irish case                                                                                                                                                                                                                                                                                                                                         
  2009                         DIRA                      Deficiency of Interleukin 1 Receptor Antagonist                                   17                       9/8             1 Turkish family             23        Recessive                 *IL1RN*            Interleukin 1                                        2q13                      c.-64_1696del, p.IL1F9_IL1RNdel
  1 Lebanese                   22                        receptor antagonist                                                                                                                                                                                                                                                                           
  family                       22                                                                                                                                                                                                                                                                                                                      
  2 Dutch families             22                        c.213_227del, p.Asp72_Ile76del                                                                                                                                                                                                                                                                
  1 Dutch case                 22                                                                                                                                                                                                                                                                                                                      
  1 Canadian case              22,27                                                                                                                                                                                                                                                                                                                   
  2 Puerto-Rican cases         25                                                                                                                                                                                                                                                                                                                      
  2 Brazilian cases            24,26                                                                                                                                                                                                                                                                                                                   
  2 Unknown                                                                                                                                                                                                                                                                                                                                            
  3 Dutch,                                                                                                                                                                                                                                                                                                                                             
  1 Lebanese,                                                                                                                                                                                                                                                                                                                                          
  1 Turkish,                                                                                                                                                                                                                                                                                                                                           
  1 from unknown ancestry                                                                                                                                                                                                                                                                                                                              
  2011                         DITRA                     Deficiency of Interleukin                                                         66                       26/37           3 Tunisian families          30        Recessive                 *IL36RN*           Interleukin 36 receptor antagonist                   2q13                      c.80C\>T, p.Leu27Pro
  1 Algerian family            9                                                                                                                                                                                                                                                                                                                       
  36 Receptor Antagonist       19 European cases         32,35,37                                                                          c.338C\>T, p.Ser113Leu                                                                                                                                                                                      
  10 Asian cases               35                        c.28C\>T, p.Arg10\*                                                                                                                                                                                                                                                                           
  6 Tunisian cases             30                                                                                                                                                                                                                                                                                                                      
  6 German cases               36                                                                                                                                                                                                                                                                                                                      
  3 Japanese cases             33,34                                                                                                                                                                                                                                                                                                                   
  1 Spanish case               9                                                                                                                                                                                                                                                                                                                       
  1 Turkish case               36                                                                                                                                                                                                                                                                                                                      
  1 Iraqi case                 36                                                                                                                                                                                                                                                                                                                      
  1 Russian case               37                                                                                                                                                                                                                                                                                                                      
  2012                         PSORS2                    Psoriasis susceptibility 2                                                        45                       24/21           1 European family            42        Dominant                  *CARD14*           Caspase recruitment domain-containing protein 14     17q25.3                   c.349G\>A, p.Gly117Ser
  1 Taiwanese family           42                                                                                                                                                                                                                                                                                                                      
  1 Tunisian family            43                                                                                                                                                                                                                                                                                                                      
  3 German cases               36                                                                                                                                                                                                                                                                                                                      
                               PRP                       Pityriasis Rubra Pilaris                                                          17                       9/8             4 Israeli families           41                                                                                                                                    
  2012                         DSAP                      Disseminated Superficial Actinic Porokeratosis                                    \>45                     21/16/ND        20 Chinese families,         48.49     Dominant                  *MVK*              Mevalonate Kinase                                    12q24                     C.604G\>A
  p.Gly202Arg                                                                                                                                                                                                                                                                                                                                          
  6 Chinese cases                                                                                                                                                                                                                                                                                                                                      
  2010                         ALDD (JMP, NNS, CANDLE)   Autoinflammation, lipodystrophy, and dermatosis syndrome                          40                       26/14           22 Japanese families         53,57     Recessive                 *PSMB8*            Proteasome Subunit,                                  6p21.32                   c.224C\>T, p.Thr75Met
  1 Portuguese family          56                        Beta-Type, 8                                                                      c.602G\>T,                                                                                                                                                                                                  
  1 Mexican family             56                        p.Gly201Val                                                                                                                                                                                                                                                                                   
  3 Hispanic cases             54                                                                                                                                                                                                                                                                                                                      
  3 Spanish cases              54                                                                                                                                                                                                                                                                                                                      
  2 American cases             54                                                                                                                                                                                                                                                                                                                      
  1 Japanese case              53                                                                                                                                                                                                                                                                                                                      
  1 Israeli case               54                                                                                                                                                                                                                                                                                                                      
  1 Italian case               9                                                                                                                                                                                                                                                                                                                       
  2012                         APLAID                    Autoinflammation, Antibody deficiency, and Immune Dysregulation syndrome          2                        1/1             1 family of unknown origin   14        Dominant                  *PLCG2*            Phospholipase C, gamma 2                             16q23.3                   ND
  2012                         NA                        Autoinflammatory syndrome with pyogenic bacterial infection and amylopectinosis   3                        1/2             1 French family              15        Recessive                 *RBCK1*            RANBP-Type and C3HC4-Type Zinc Finger-Containing 1   20p13                     ND
  1 Italian case                                                                                                                                                                                                                                                                                                                                       

\* Commonly used disease names as defined in Table  [2](#T2){ref-type="table"} \*\* Genetically confirmed. \*\*\* "Family" refers to multiplex families; "Case" refers to sporadic patients \*\*\*\* Approved HUGO.

NA: Not assigned yet. ND: Not determined.

###### 

Clinical features of rare recently recognized monogenic autoinflammatory diseases

  **OMIM**                                     **ORPHA-CODE**                **Disease acronyme**   **Disease extended name\***                                                       **Synonyms**   **Age at onset**                                                                                          **Key symptoms**   **Differential diagnosis**       **Treatment**                                                                                                                                                                                                                                                                                                                                                                                                                        
  -------------------------------------------- ----------------------------- ---------------------- --------------------------------------------------------------------------------- -------------- --------------------------------------------------------------------------------------------------------- ------------------ -------------------------------- --------------- ----------------------------------------------------------------------------------------------- ------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------
  612373                                       168569 254707 254712 254723   **H Syndrome**         Histiocytosis-lymphadenopathy plus syndrome                                       PHID           Pigmentary Hypertrichosis and non-autoimmune Insulin-dependent Diabetes mellitus                          FHC                Faisalabad Histiocytosis         SHML            Sinus Histiocytosis with Massive Lymphadenopathy                                                Infancy                         Histiocytosis                                                                                                                                                     FCAS2                                                                                                              NSAID (IL-1 and TNF blockades not effective)
  FCAS3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  ALDD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  Other causes of insulin-dependent diabetes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  611762                                       247868                        FCAS2                  Familial Cold Autoinflammatory Syndrome 2                                         **NAPS12**     NLRP12 Associated Periodic Syndrome                                                                       **NLRP12AD**       NLRP12-associated disorder                                                                                                                       Infancy Childhood Adulthood     Urticaria, fever, myalgia, arthralgia                                                                                                                             FCAS1 FCAS3                                                                                                        NSAID (IL-1 blockades not effective)
  612852                                       210115                        OMPP                   Osteomyelitis, sterile Multifocal, with Periostitis and Pustulosis                **DIRA**       Deficiency of Interleukin 1 Receptor Antagonist                                                                                                                                                                                                                               Neonatal                        Neutrophilic pustular dermatosis, periostitis, aseptic multifocal osteomyelitis                                                                                   PSORP Other dermatologic and infectious conditions                                                                 IL1 blockades (NSAID not effective)
  614204                                       247353                        PSORP                  Pustular Psoriasis, Generalized                                                   **DITRA**      Deficiency of Interleukin 36 Receptor Antagonist                                                          GPP                Generalized Pustular Psoriasis                                                                                                                   Infancy, Childhood, Adulthood   Diffuse erythematous pustular rash, fever, malaise and diffuse pain, systemic inflammation                                                                        OMPP Other autoinflammatory diseases                                                                               NSAID, Vitamin D3, Acitretin, TNF and IL-1 blockades
  602723                                       NA                            PSORS2                 **Psoriasis susceptibility 2**                                                                                                                                                                                                                                                                                                                                                 Variable                        Round, well circumscribed erythematous plaques covered by a thick silver scale with a predilection for elbows, knees, scalp, lumbosacral and anogenital regions   Other papulosquamous disorders                                                                                     Corticosteroids, calcineurin inhibitor, calcipotriene, emollients, keratolytic agents, ultraviolet light, retinoids, methotrexate, cyclosporine, anti-TNF agents
  173200                                       2897                          **PRP**                Pityriasis Rubra Pilaris                                                                                                                                                                                                                                                                                                                                                       Neonatal Early childhood        Small keratotic follicular papules, disseminated salmon-colored scaly plaques surrounding islands of normal skin, diffuse red-orange palmoplantar keratoderma     Phrynoderma (vitamin A deficiency), psoriasis, erythrokeratodermia, other causes of cornification                  Emollients, topical corticosteroids, tazarotene, keratolytic agents, calcineurin inhibitor, systemic retinoids, TNFα blocking agents
  175900                                       79152                         POROK3                 Porokeratosis 3, Disseminated Superficial Actinic Type                            **DSAP**       Disseminated Superficial Actinic Porokeratosis                                                                                                                                                                                                                                Adult                           UV sensitive, Epidermal cornification, round and brownish lesions                                                                                                 Neoplastic or hyperplastic squamous proliferations                                                                 Cryotherapy, topical reagents, electrodessication, laser ablation, photodynamic therapy
  256040                                       2615                          ALDD                   Autoinflammation, LipoDystrophy, and Dermatosis syndrome                          **JMP**        Joint contractures, muscle atrophy, Microcytic anemia, and Panniculitis-induced lipodystrophy syndrome.   **NNS**            Nakajo-Nishimura Syndrome        **CANDLE**      Chronic Atypical Neutrophilic Dermatosis with Lipodystrophy and Elevated temperature syndrome   Neonatal                        Fever, skin rash, panniculitis, lipoatrophy                                                                                                                       Still's disease, CINCA, mucopolysaccharidosis, lupus, dermatomyositis, laminopathies, Aicardi Goutieres syndrome   NSAID, Interferon γ, JAK inhibitors?
  614878                                       324530                        **APLAID**             Autoinflammation, antibody deficiency, and immune dysregulation syndrome                                                                                                                                                                                                                                                                                                       ND                              Neutrophilic skin lesions, IBD, recurrent sino pulmonary infections                                                                                               Other immunodeficiencies, IBD, PLAID                                                                               ND
  NA                                           329173                        NA                     Autoinflammatory syndrome with pyogenic bacterial infection and amylopectinosis                                                                                                                                                                                                                                                                                                ND                              ND                                                                                                                                                                ND                                                                                                                 ND

\*Approved OMIM; NA Not assigned yet; ND: too few patients to delineate clear criteria. Commonly used disease names are in bold text.

NSAID: nonsteroidal anti-inflammatory drugs.

CINCA: Chronic, Infantile, Neurologic, Cutaneous and Articular syndrome, IBD: inflammatory bowel disease, PLAID: PLCg2-Associated antibody Deficiency.

Rare recently recognized monogenic autoinflammatory diseases
------------------------------------------------------------

The correct diagnosis of monogenic autoinflammatory diseases relies on the physicians' awareness. Due to the rarity of these disorders, a very low number of cases are reported. For example, less than five patients with clear autoinflammatory features and causative mutations have been published for each of H syndrome \[[@B10]-[@B13]\], Autoinflammation and PLCG2-associated antibody deficiency and Immune Dysregulation syndrome (APLAID) \[[@B14]\], and RANBP-Type and C3HC4-Type Zinc Finger-Containing 1 (RBCK1)-related disease \[[@B15]\]. These three conditions are thus cited in Tables  [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"} only. Moreover, as mutations in these rare conditions have apparently systemic and pleiotropic effects, the patients' clinical spectrum is heterogeneous and not yet completely delineated. Molecular analysis of the candidate genes may also fail to detect mutations. Consequently, the frequency of these diseases is unknown and too little feedback and data exist on the clinical significance and penetrance of the variants to ensure adequate genetic counseling for these patients.

NLRP12 Associated Periodic Syndrome (NAPS12)
--------------------------------------------

This disease is characterized by recurrent periods of fever, combined with various systemic manifestations such as myalgia, arthralgia, headaches and skin urticarial-like rash although some patients may display arthralgia or myalgia only \[[@B16]-[@B18]\]. The most severely affected patients suffer from neurosensory signs (headache, deafness) \[[@B18]\]. The inflammatory attacks last 5-10 days and are triggered by physical exertion or cold exposure. These attacks can be very disabling in everyday life and can have a major impact on school attendance or work. The disease appears to be more active in children and teenagers than in adults.

Treatment is not standardized and no long-term medication has proven to be effective. Patients with a mild phenotype may be treated symptomatically with non-steroidal anti-inflammatory drugs. There is currently no therapeutic option available for patients with the most severe phenotype, and long-term treatment with interleukin (IL)-1 inhibitors (Anakinra, Kineret®) failed in the two cases tested \[[@B19]\].

The genetic defect of this disease was identified in 2008 \[[@B18]\] as a mutation in the gene encoding NLR pyrin domain-containing protein 12 (*NLRP12*) belonging to the intracellular Nod-like receptor (NLR) family. This protein is an intracellular sensor of the innate immune system, that regulates inflammatory processes through inhibition of nuclear factor kappa B (NF-κB) \[[@B18]\] and IL1β \[[@B16]\] signaling. *NLRP12* mutations are likely responsible for a loss of protein function resulting in upregulation of this pro-inflammatory pathway. However, the exact role of NLRP12 remains unknown. It may participate in the formation of an NLRP3-independent inflammasome and be crucial for the recognition of intracellular pathogens. NLRP12 could also play an important role in the homeostasis of the gut by controlling the genesis of inflammatory diseases of the gastrointestinal tract and/or colorectal cancer \[[@B20],[@B21]\]. Two unambiguous mutations, c.850C \> T, p.Arg284\*; c.2072 + 2dupT, p.Val635Thrfs\*12 \[[@B18]\] as well as two missense substitutions c.1054C \> T, p.Arg352Cys \[[@B16]\] and c.882C \> G, p.Asp294Glu \[[@B17]\] were proven pathogenic through functional studies.

Deficiency of Interleukin 1 Receptor Antagonist (DIRA)
------------------------------------------------------

Sterile multifocal osteomyelitis with periostitis and pustulosis (OMPP) is more commonly referred to as DIRA \[[@B22]\]. DIRA is an early-onset auto-inflammatory disease that presents with neutrophilic pustular dermatosis, periostitis, aseptic multifocal osteomyelitis, and high acute-phase reactants. Patients develop pustular skin rashes, gastrointestinal reflux, and multifocal osteomyelitis during the neonatal period. One patient presented with early onset intrauterine disease and intrauterine fetal demise \[[@B23]\]. Massive systemic inflammatory syndrome resulting in patient death has been described \[[@B22]\]. Other manifestations include osteopenia, interstitial pneumonia often causing hypoxemia and dyspnea or localized ground-glass opacities and areas of atelectasis at chest computed tomography, vesicular stomatitis, mouth ulcers, ribs widening, periosteal reaction, joint swelling, cervical vertebra fusion, hepatosplenomegaly, thrombosis and vasculopathy \[[@B22],[@B24]-[@B26]\]. Skin biopsies show neutrophilic epidermal and dermal infiltration, concomitant superficial folliculitis, with subcorneal localization of the pustules. Differential diagnosis includes other autoinflammatory conditions especially deficiency of the Interleukin 36 receptor antagonist (DITRA), dermatologic conditions (infantile pustular psoriasis, tinea, bacterial folliculitis, scabies, eosinophilic pustular folliculitis, erythema toxicum neonatorum, transient neonatal pustular melanosis...), and infectious diseases (arthritis, osteomyelitis).

Antibiotics and conventional disease-modifying antirheumatic drugs including steroids are of limited benefit, however blocking IL-1 signaling with anakinra dramatically improved clinical symptoms within days, resolving osteolytic lesions, normalizing acute-phase reactants, and permitting appropriate growth \[[@B22],[@B24]-[@B29]\]. Patients with DIRA need to remain on lifelong IL-1 inhibitory therapy. Previous attempts at stopping or weaning anakinra have resulted in disease flares.

The disease is caused by mutations of the gene encoding the protein IL1RA. This protein is a natural antagonist of the potent proinflammatory interleukins-1 cytokines and mutations result in over activity of IL-1α as well as IL-1beta is expected in case of IL-1RA deficiency Two founder deletions were reported, one Puerto Rican: c.-64_1696del, p.IL1F9_IL1RNdel \[[@B22],[@B24],[@B27]\], and one Brazilian: c.213_227del, p.Asp72_Ile76del \[[@B25]\].

Deficiency of IL-36 receptor antagonist (DITRA)
-----------------------------------------------

Interleukin-36-receptor antagonist deficiency is a hereditary auto-inflammatory disease characterized by repeated flares of generalized pustular psoriasis (GPP). The flares include sudden diffuse pustular erythematous rash associated with high fever, general malaise, systemic inflammation and sometimes ^\'^geographic tongue' and nail dystrophy \[[@B30]\]. Organ inflammation such as cholangitis can occur during the disease course. In most patients, symptoms develop during childhood though the age of onset can vary considerably. Neonatal onset has also been reported. Failure to thrive may occur. Elevated C-reactive protein serum levels and marked leukocytosis are constant during disease attacks. Differential diagnosis includes other causes of GPP, mainly DIRA \[[@B22]\], in cases where symptoms appear during the first weeks of life.

There is no established treatment. Topical and oral steroids, vitamin D3, acitretin and anti-TNF-α, are effective. Our group has recently successfully treated an infant with DITRA not responding to topical and oral steroids or to acitretine with anakinra \[[@B31]\].

IL-36 receptor antagonist (IL-36RA) is a natural antagonist of IL-36α, IL-36β and IL-36γ, three cytokines belonging to the IL-1 family. Mutations result in decreased IL-36RA antagonistic effects due to a reduction of both IL-36RA protein stability and affinity for its receptor, the consequence of which is uncontrolled inflammation \[[@B30],[@B32]-[@B37]\]. The high resulting expression of IL-36R and of the three agonists in epithelial tissues like skin likely causes GPP, the main clinical feature in all DITRA patients. In a recent study, Setta-Kafetzi et al. identified IL36RN variant alleles in palmarplantar pustulosis and acrodermatitis continua of hallopeau, two forms of GPP genetically distinct from psoriasis vulgaris \[[@B35]\].

Among the most frequent genetic alterations are one Tunisian founder missense mutation: c.80C \> T, p.Leu27Pro1; one European recurrent missense mutation: c.338C \> T, p.Ser113Leu2; and one Japanese founder nonsense mutation: c.28C \> T, p.Arg10\*3.

Psoriasis susceptibility (PSORS)2 and pityriasis rubra pilaris (PRP)
--------------------------------------------------------------------

Psoriasis is a common and chronic immune-mediated inflammatory disease of the skin affecting approximately 2% of individuals of European descent with a strong genetic susceptibility \[[@B38]\]. Classic lesions consist of round, well-circumscribed erythematous plaques covered by a thick silver scale with a predilection for elbows, knees, scalp, lumbosacral and anogenital regions. Fingernail plate involvement includes pitting and distal onycholysis. Inverse psoriasis (flexural distribution), guttate psoriasis, pustular or erythrodermic psoriasis are other clinical variants. Pityriasis rubra pilaris (PRP) is a chronic skin disorder of abnormal keratinization classified by Griffiths into five types based on the age of onset and the clinical features \[[@B39]\]. Familial PRP belongs to the type V group (atypical juvenile) and accounts for about 5% of all cases. This chronic skin disorder usually presents at birth or appears during early childhood. It is characterized by small keratotic follicular papules forming disseminated salmon-colored scaly plaques that surround islands of normal skin, and diffuse red-orange palmoplantar keratoderma. Lesions typically progress rostral to caudal. While nails can be dystrophic, pitting of nails is not a feature of this disease. Skin biopsies can be performed if the clinical features or the responses to treatment are unusual. Histopathological analysis shows psoriasiform hyperplasia presenting as acanthosis with elongation of the rete ridges, parakeratosis and mononuclear cell infiltrate. Compared to psoriasis, the epidermal hyperplasia in PRP is more irregular, the granular layer is preserved, follicular plugging is characteristic and neutrophils in the stratum corneum are not essential. Differential diagnosis of psoriasis includes other papulosquamous disorders. PRP shows clinical features similar to phrynoderma (vitamin A deficiency), psoriasis, erythrokeratodermia and other causes of cornification.

Management of psoriasis includes patient education, topical therapy (corticosteroids, calcineurin inhibitor, calcipotriene, emollients, keratolytic agents), ultraviolet light, and systemic therapy (retinoids, methotrexate, cyclosporine and anti-TNF agents). The treatment of PRP is often disappointing. Milder cases of the disease can be treated with emollients, topical corticosteroids, tazarotene, keratolytic agents or calcineurin inhibitor whereas systemic retinoids and/or TNFα blocking agents are required in severe cases.

The prognosis of both disorders is that of most chronic diseases, with spontaneous remissions and exacerbations. Arthritis is present in about one fourth of psoriasis patients, and there is an increased risk of metabolic syndromes and cardiovascular diseases \[[@B40]\].

Both phenotypes have been associated to CAspase Recruitment Domain-containing protein 14 (*CARD14*) mutations \[[@B36],[@B41]-[@B43]\]. CARD14 is an epidermal regulator of NF-κB transcription factor. Mutations in CARD14 initiate a process that includes inflammatory cell recruitment by keratinocytes and perpetuate a vicious cycle of epidermal inflammation and regeneration that cause the abnormal keratinization. More specifically, c.349G \> A, p.Gly117Ser (the most prevalent mutation), and c.413A \> C, p.Glu138Ala (a *de novo* mutation) were shown to lead to enhanced NF-κB activation and upregulation of a subset of psoriasis-associated genes in keratinocytes \[[@B43]\].

Disseminated Superficial Actinic Porokeratosis (DSAP)
-----------------------------------------------------

This disease described in 1966 by Chernosky \[[@B44]\] represents the most common form of porokeratosis, a group of diseases characterized by epidermal cornification with epidermal cell hyperproliferation and premature apoptosis of keratinocytes. Triggers include ultraviolet light exposure and immunosuppression. Multiple small (0.5-1 cm) round and brownish lesions surrounded by a hyperkeratotic rim develop on sun-exposed areas of the skin particularly on the lower legs and forearms. Lesions usually appear in summer and improve or disappear during winter. The disease usually starts during the third or fourth decades of life, and rarely affects children. While it is usually benign, squamous cell carcinoma or Bowen's disease may occasionally develop within the lesions.

Histopathological examination of the skin sampled from the edge of the peripheral rim characteristically shows an angulated cornoid lamella and a parakeratotic column overlying an area of epidermis with an absent or reduced granular layer \[[@B45]\]. Differential diagnosis includes neoplastic or hyperplastic squamous skin lesions.

Cryotherapy, topical reagents (retinoids, imiquimod, 5-fluorouracil, keratolytic), electrodessication, laser ablation or photodynamic therapy are used to destroy the abnormal keratinocyte clones \[[@B46]\].

The mode of inheritance is dominant however many sporadic cases of porokeratosis have been described \[[@B47]\]. Mutations in the MeValonate Kinase (*MVK*) gene were found in DSAP patients \[[@B48],[@B49]\]. The MVK enzyme is involved in the biosynthesis of cholesterol and isoprenoid. It is also thought to play a role in regulating calcium-induced keratinocyte differentiation and could protect keratinocytes from apoptosis induced by type A ultraviolet radiation. All genetically confirmed patients are of Chinese origin. Fourteen different mutations have been found, among which, 10 accounted for one third of the familial cases. Mutations in this gene were initially demonstrated as responsible for recessive complete (mevalonic aciduria \[[@B50]\], OMIM 610377) and incomplete (hyperIgD syndrome \[[@B51],[@B52]\], OMIM 260920) mevalonate kinase deficiency.

Autoinflammation, LipoDystrophy, and Dermatosis syndrome (ALDD)
---------------------------------------------------------------

ALDD is a systemic inflammatory condition starting within the first months of life, and comprising elevated fever, panniculitis with lipoatrophy, purplish and swollen eyelids, arthralgia, developmental retardation, and increased acute phase reactants \[[@B53],[@B54]\]. Key symptoms include a persistent fever of \>38.5°C, steroid-sensitive erythema nodosum-like (edematous and purpuric) plaques, long clubbed fingers, hyperhidrosis, myositis, hepatosplenomegaly, macroglossia, facial and limbs lipoatrophy, and developmental (height, weight and IQ) retardation. Skin biopsies show immature myeloid-lineage cells with mitoses. Some patients may have joint contracture, auricular and nasal chondritis, and calcification of the basal ganglia. Acute cardiovascular event is the leading cause of death in these patients for whom life expectancy is notably reduced. Differential diagnosis includes other autoinflammatory conditions, in particular Sweet's syndrome, Still's disease and Chronic, Infantile, Neurological, Cutaneous and Articular (CINCA) syndrome, storage diseases (mucopolysaccharidosis), lupus, dermatomyositis, laminopathies (progeroid syndromes), and other interferonopathies like Aicardi Goutieres syndrome, an interferon type I related disease. Biological findings include microcytic or normocytic anemia, thrombopenia (rare), mild increase in levels of amino transferase enzymes, perturbation of glucose and lipid metabolism (hyperglycemia and glucose intolerance, increased cholesterol and triglycerides), increased erythrocyte sedimentation rate and γ globulins levels, and some markers of autoimmunity (antinuclear and anti-neutrophilic cytoplasmic auto-antibodies, lupus anticoagulant, positive Coombs test).

Management of these patients is by palliative care**.** The need for steroids is very high even in combination with anti IL-1, anti IL-6 or anti-TNF treatments. Drugs targeting interferon γ are warranted. JAK kinase inhibitors are currently under clinical trials at the National Institute of Health, Bethesda, USA \[[@B55]\].

Most (N = 28) of the reported patients carried homozygous mutations in the Proteasome Subunit, Beta-Type, 8 (*PSMB8*) gene \[[@B53],[@B54],[@B56],[@B57]\]. This gene encodes β5i, a catalytic subunit of the immunoproteasome, an intracellular protease complex specialized for degradation of polyubiquitinated proteins. This ubiquitin-proteasome system degrades unnecessary proteins and regulates the cell cycle, gene repair and nuclear factor NF-κB activation \[[@B53]\]. The mutated protein impairs the assembly of this immunoproteasome. One nonsense (c.405C \> A, p.Cys135\*) \[[@B54]\] and five missense mutations of which two are recurrent (c.224C \> T, p.Thr75Met and c.602G \> T, p.Gly201Val) have been reported \[[@B9]\]. As the prognosis is so severe, prenatal diagnosis can be discussed.

Conclusions
===========

Hereditary recurrent fevers, as well as Majeed syndrome, Blau syndrome, and Pyogenic sterile Arthritis, Pyoderma gangrenosum and Acne (PAPA) syndrome, have been extensively reviewed since the concept of autoinflammation was created in 1999 \[[@B58]\]. However, very little information has been assembled regarding the phenotype, genetics and epidemiology of the more recently discovered autoinflammatory disorders. Here in this review, we aimed to offer novel diagnostic options to those patients for whom a genetic link could not be established. More than 25 autoinflammatory genes were listed during the last international conference on autoinflammation, Lausanne, 23-26 May, 2013, including at least five to six new ones in the pipeline. Both phenotype and genotype heterogeneity have been described which further hinders correct diagnosis and highlights the necessity for a gene and disease nomenclature consensus. A systematic in-depth description of the clinical features of these patients has been undertaken thanks to the Eurofever initiative \[[@B59],[@B60]\]. Massively parallel sequencing approaches should help in identifying the causative gene among those already known or novel genes through whole exome or genome sequencing. Development of such innovative genetic diagnostic tools is in progress through an International network (I Touitou, personal communication).

The correct diagnosis of these diseases is essential for the relevant management of patients affected by rare autoinflammatory diseases as remarkably effective therapies have been developed recently which have the potential to avoid the risk of fatal complications such as amyloidosis, or sensorineural impairment. Rarely emphasized yet equally important is being able, even after many years as in some cases, to name the patient's disease, which can be extremely useful from a psychological point of view.

Competing interests
===================

The authors declare that they have no competing interests.

Authors' contributions
======================

IT and IKP conceived and designed the manuscript. IKP coordinated and assigned the writing of the different disease items: CG: DIRA; LR: DITRA; IKP: ALDD; VH: NALP12; MP: DSAP and PRP. IT collected the data, assembled the first draft, and polished the manuscript. All authors read the final manuscript and gave approval for the version to be published. All authors read and approved the final manuscript.

Authors' information
====================

All authors are members of the French reference centre for autoinflammatory diseases (CeRéMAI, \[<http://asso.orpha.net/CEREMAI/EN/index.html>\]) coordinated by IKP. IT developed infevers \[<http://fmf.igh.cnrs.fr/ISSAID/infevers/>\], an online registry devoted to autoinflammatory disease mutations.

Acknowledgements
================

This work was supported by the French Ministry of Health, and the Kremlin Bicêtre, Versailles and Montpellier hospitals. We thank Angloscribe for editing the manuscript for English language.
